Human Immunodeficiency Virus (HIV) Clinical Trial
— POISEOfficial title:
PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naïve to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial
Verified date | May 2014 |
Source | Janssen Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada:IRBCanada: Ethics Review Committee |
Study type | Observational |
The purpose of this study is to evaluate tolerability of darunavir (PREZISTA) or etravirine (INTELENCE) in patients infected with human immunodeficiency virus type 1 (HIV-1) who are naïve to these medications and in patients who have experienced tolerability issues on their current or prior combination antiretroviral therapy (cART). The tolerability is evaluated by switching the patients from their previous or current combination antiretroviral therapy (cART) to either darunavir or etravirine.
Status | Completed |
Enrollment | 77 |
Est. completion date | April 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Have a documented HIV-1 infection - Have 1 or more significant symptoms with at least grade 2 toxicity on the Division of AIDS Toxicity "DAIDS grading scale" on current or prior combination antiretroviral therapy (cART) regimen (current or prior cART including regimens consisting of 2 Nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent with the exception of darunavir or etravirine) - Have stable response to current cART ie, have an HIV-plasma viral load [number of virus in blood] at screening <400 copies/mL (undetectable) or last plasma viral load on prior regimen within the previous 6 months <400 copies/mL) - Must not have resistance to Primary HIV protease inhibitor medicines Exclusion Criteria: - Has been Infected with HIV-2 - Has received previous treatment with darunavir or etravirine or non-HAART (Highly Active Antiretroviral Therapy) regimen - Has had prior virologic failure to 2 or more regimens or single virologic failure on prior cART - Has a documented resistance to darunavir and etravirine - Is currently using any drug contraindicated in the current Canadian Product Monograph for darunavir or etravirine |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Janssen Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in the patient's total score of the HIV Symptom Distress Module (HIV-SDM) | HIV-SDM is a questionnaire consisting of 20 questions related to all the symptoms which the patient might have had during the past four weeks. For each question patient has to select appropriate answer related to the symptoms: "0 = I do not have this symptom; 1 = I have this symptom and it doesn't bother me; 2 = it bothers me a little; 3 = it bothers me; 4 = it bothers me a lot". Total score of HIV-SDM is then calculated for all the 20 items. | Baseline (Day 1), Week 4, 12 and 24 | No |
Secondary | Number of participants with Maintenance/achievement of virologic suppression at Week 24 | Virologic suppression is decrease in the number of virus in blood. Number of participants with virologic suppression (who achieved virologic suppression) as well as the Number of participants who maintained virologic suppression will be summarized. | Baseline and Week 24 | No |
Secondary | Number of participants with disappearance by Week 4 of at least one bothersome symptom identified at baseline by patient on HIV-SDM | The bothersome symptoms (defined as those reported as 'It bothers me a lot' or 'It bothers me') at baseline will be identified for each patient. The number of participants who report the disappearance of at least one of the bothersome symptoms (eg, reported as 'It bothers me a little', 'It does not bothers me', 'I do not have the symptom') by Week 4 will be summarized. | Baseline and Week 4 | No |
Secondary | Number of participants with maintenance of disappearance by Week 12 and Week 24 of at least one bothersome symptom identified at baseline by patient on HIV-SDM | The number of participants who report the maintenance of the disappearance of at least one of the bothersome symptoms (eg, reported as It bothers me a little, 'It does not bothers me', 'I do not have the symptom') at Week 12 and Week 24 will be summarized. | Baseline, Week 12 and Week 24 | No |
Secondary | Number of participants with Maintenance/increase in CD4 cell count. | CD4 cells (a type of white blood cells) are circulating in blood and gives an idea of how strong the HIV positive person's immune system really is. The values of CD4 cell counts will be summarized using mean, standard deviations, minimum and maximum at baseline and Week 24. In addition, the number of participants with maintenance or increase in CD4 cell counts will be summarized. | Baseline and Week 24 | No |
Secondary | Comparison of change in HIV-SDM scores between those participants who were on or off ARTs at baseline | On and off ARTs is patients taking HIV medications and patients not taking HIV medications. The HIV-SDM change from baseline scores will be summarized using basic statistics (mean, standard deviations, minimum and maximum) by whether the patient is on or off ART at baseline. | Baseline, Week 4, Week 12 and Week 24 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
Completed |
NCT02234492 -
The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients
|
Phase 4 | |
Completed |
NCT02027441 -
Enhanced Prevention in Couples: Feasibility Study #2
|
N/A | |
Completed |
NCT01685372 -
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
|
Phase 2 | |
Completed |
NCT02165202 -
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
|
Phase 2 | |
Completed |
NCT01449006 -
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
|
Phase 4 | |
Completed |
NCT02572401 -
Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men
|
N/A | |
Terminated |
NCT01448486 -
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
|
Phase 4 | |
Completed |
NCT04122404 -
POC Strategies to Improve TB Care in Advanced HIV Disease
|
N/A | |
Completed |
NCT03290755 -
Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux
|
||
Completed |
NCT02974998 -
Cape Town Young Women's Health CoOp
|
N/A | |
Completed |
NCT01516970 -
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
|
Phase 3 | |
Completed |
NCT01997346 -
Multi-level Determinants of Starting ART Late: Aim 2
|
N/A | |
Active, not recruiting |
NCT01875952 -
Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
|
Phase 4 | |
Completed |
NCT01199939 -
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
|
Phase 2 | |
Completed |
NCT03783130 -
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
|
Phase 1 | |
Active, not recruiting |
NCT05657106 -
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
|
N/A | |
Not yet recruiting |
NCT05727033 -
Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections
|
N/A | |
Completed |
NCT01053741 -
Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
|
N/A | |
Completed |
NCT02946047 -
The Effect of Ixazomib on the Latent HIV Reservoir
|
Phase 1/Phase 2 |